ClinicalTrials.gg
Enrolling by invitationNCT07652294SKYLINE-LTEUpdated Nov 9, 2026

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

A Phase 2 interventional study of SPY001 and SPY002 in Ulcerative Colitis, Inflammatory Bowel Diseases and Colitis, sponsored by Spyre Therapeutics, Inc.. Enrolling by invitation at 100 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Spyre Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026First sites in 6 new countries48 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
645
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.

Planned enrollment
34th of 215
645 · median 196
Started
2026
with 11 others
Phase 2
104 of 221
15 open now
Primary completion
2029-03
later than 52 of 64 live
Registered
219th of 221
by date

Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 34th largest by planned enrollment of the 215 interventional ones that give a count, is one of 12 that started in 2026, is one of 104 in phase 2, reaches primary completion later than 52 of the 64 other live ones, and was the 219th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Colitis, Ulcerative with a site in Poland, or all of them as a file.
02

Study summary

This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study).

Read the detailed description

This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study) who have completed Part A and are deemed to be receiving clinical benefit, completed Part B, or met escape criteria in Part B. The primary aim of this LTE study is to characterize the long-term safety of various investigational drugs, to offer participants the option to extend treatment if they are clinically benefiting, or if they have not achieved sufficient clinical benefit (particularly placebo insufficient responders), to offer the opportunity to receive investigational drug.

03

Conditions studied

  • Ulcerative Colitis
  • Inflammatory Bowel Diseases
  • Colitis
  • Colitis, Ulcerative

Keywords

  • Inflammatory Bowel Diseases
  • Colitis
  • Colitis, Ulcerative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet 1 of the following criteria from Study SPY123-201:

  1. Completed Part A and deemed to be receiving clinical benefit by the judgement of the Investigator
  2. Completed Part B
  3. Participated in Part B and met escape criteria per the SPY123-201 protocol (ie, did not achieve sufficient improvement after the induction treatment period [ITP] or experienced disease worsening during the maintenance treatment period [MTP]).

Exclusion criteria

Exclusion Criteria:

  1. Met any treatment discontinuation criteria from Study SPY123-201.
  2. Is on any of the following prohibited medications:

    1. (eg, azathioprine, 6-mercaptopurine [6-MP], or methotrexate)
    2. Systemic tacrolimus, systemic cyclosporine, oral mycophenolate mofetil (MMF), immunoadsorption columns (such as Prosorba columns), penicillamine, leflunomide, thalidomide, or any other medications that may have immunosuppressive effects
    3. Any marketed advanced therapy (ie, biologic or small molecule)
    4. Any therapy other than SPY123-201 study drug
    5. Total parenteral nutrition
  3. Development of any new, unstable, or uncontrolled metabolic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological (including current and past neurological symptoms suggestive of demyelinating disease), respiratory, endocrine, or psychiatric disorder, acute or chronic infectious diseases, suspected or confirmed immunodeficiency, and suspected or confirmed , as determined by the Investigator that is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.
  4. Ongoing infection requiring oral or intravenous antimicrobial therapy on Day 1.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
645 participants (estimated)

Study arms

  • Experimental
    SPY001 Dosing Regimen 1

    Participants will receive SPY001

    Drug: SPY001

  • Experimental
    SPY002 Dosing Regimen 1

    Participants will receive SPY002

    Drug: SPY002

  • Experimental
    SPY003 Dosing Regimen 1

    Participants will receive SPY003

    Drug: SPY003

  • Experimental
    SPY001 Dosing Regimen 2

    Participants will receive SPY001

    Drug: SPY001

  • Experimental
    SPY002 Dosing Regimen 2

    Participants will receive SPY002

    Drug: SPY002

  • Experimental
    SPY003 Dosing Regimen 2

    Participants will receive SPY003

    Drug: SPY003

  • Experimental
    SPY001 & SPY002

    Participants will receive SPY001 and SPY002

    Drug: SPY001 · Drug: SPY002

  • Experimental
    SPY001 & SPY003

    Participants will receive SPY001 and SPY003

    Drug: SPY001 · Drug: SPY003

  • Experimental
    SPY002 & SPY003

    Participants will receive SPY002 and SPY003

    Drug: SPY002 · Drug: SPY003

  • Experimental
    SPY002 Dosing Regimen 3

    Participants will receive SPY002

    Drug: SPY002

Interventions

  • DrugSPY001

    Experimental

    Also known as: SPY001-001

  • DrugSPY002

    Experimental

    Also known as: SPY002-091

  • DrugSPY003

    Experimental

    Also known as: SPY003-207

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experienced an adverse event

    Incidence of treatment-emergent adverse events (TEAEs) as measured over time.

    Time frame: Week 96

Secondary outcomes

  1. Percentage of participants with endoscopic improvement

    Percentage of participants with endoscopic improvement at Week 48 will be assessed. Endoscopic improvement based on the Mayo endoscopic subscore (ranging from 0 to 3). Higher score indicates more severe disease.

    Time frame: Week 48

07

Study locations

100 sites
  • Site 023
    La Jolla, California 92037, United States
  • Site 012
    Lancaster, California 93534, United States
  • Site 007
    Kissimmee, Florida 34741, United States
  • Site 035
    Marrero, Louisiana 70072, United States
  • Site 028
    Rochester, Minnesota 55905, United States
  • Site 025
    Providence, Rhode Island 02904, United States
  • Study Site 002
    San Antonio, Texas 78229, United States
  • Site 008
    Southlake, Texas 76092, United States
  • Site 019
    Tacoma, Washington 98405, United States
  • Site 102
    Lujan de Cuyo, Mendoza Province 5505, Argentina
  • Site 103
    Rosario, Santa Fe Province 2000, Argentina
  • Site 208
    Concord, New South Wales 2139, Australia
  • Site 206
    South Brisbane, Queensland 4101, Australia
  • Site 463
    Linz, Upper Austria 4021, Austria
  • Site 461
    Salzburg, 5020, Austria
  • Site 473
    Leuven, Flemish Brabant 3000, Belgium
  • Site 471
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Site 126
    Passo Fundo, Rio Grande Sul 99010-260, Brazil
  • Site 128
    Santo André, São Paulo 09080-110, Brazil
  • Site 153
    Osorno, Los Lagos Region 5290000, Chile
  • Site 152
    Santiago, Santiago Metropolitan 8320000, Chile
  • Site 531
    Brno, 615 00, Czechia
  • Site 584
    Kutaisi, 4600, Georgia
  • Site 589
    Marneuli, 3000, Georgia
  • Site 581
    Tbilisi, 0102, Georgia
  • Site 588
    Tbilisi, 0114, Georgia
  • Site 583
    Tbilisi, 0144, Georgia
  • Site 586
    Tbilisi, 0144, Georgia
  • Site 582
    Tbilisi, 0159, Georgia
  • Site 587
    Tbilisi, 0159, Georgia
  • Site 603
    Ulm, 89081, Germany
  • Site 634
    Athens, 106 76, Greece
  • Site 654
    Békéscsaba, H-5600, Hungary
  • Site 651
    Budapest, H-1088, Hungary
  • Site 652
    Székesfehérvár, H-8000, Hungary
  • Site 673
    Legnano, Milan 20025, Italy
  • Site 672
    Negrar, Verona 37024, Italy
  • Site 424
    Amman, 11196, Jordan
  • Site 421
    Amman, 11942, Jordan
  • Site 422
    Irbid, 21110, Jordan
  • Site 423
    Irbid, 22110, Jordan
  • Site 174
    Saltillo, Coahuila 25050, Mexico
  • Site 175
    Celaya, Guanajuato 38000, Mexico
  • Site 173
    Tlajomulco de Zúñiga, Jalisco 45645, Mexico
  • Site 711
    Chisinau, MD-2025, Moldova
  • Site 715
    Chisinau, MD-2068, Moldova
  • Site 712
    Chisinau, MD2025, Moldova
  • Site 753
    Bydgoszcz, 85-229, Poland
  • Site 732
    Bydgoszcz, 85-794, Poland
  • Site 748
    Krakow, 31-501, Poland
  • Site 750
    Kłodzko, 57-300, Poland
  • Site 746
    Lodz, 91-034, Poland
  • Site 743
    Opole, 45-819, Poland
  • Site 740
    Poznan, 60-309, Poland
  • Site 736
    Rzeszów, 35-326, Poland
  • Site 744
    Sopot, 81-756, Poland
  • Site 737
    Szczecin, 71-434, Poland
  • Site 733
    Szczecin, 71-685, Poland
  • Site 752
    Tychy, 43-100, Poland
  • Site 754
    Warsaw, 02-172, Poland
  • Site 731
    Warsaw, 04-501, Poland
  • Site 738
    Wroclaw, 52-416, Poland
  • Site 734
    Wroclaw, 53-149, Poland
  • Site 747
    Wroclaw, 53-611, Poland
  • Site 742
    Wroclaw, 54-239, Poland
  • Site 781
    Bucharest, 020125, Romania
  • Site 788
    Timișoara, 300239, Romania
  • Site 802
    Belgrade, 11000, Serbia
  • Site 803
    Belgrade, 11000, Serbia
  • Site 807
    Belgrade, 11000, Serbia
  • Site 801
    Zrenjanin, 23000, Serbia
  • Site 823
    Bratislava, 811 09, Slovakia
  • Site 822
    Košice, 040 13, Slovakia
  • Site 824
    Prešov, 080 01, Slovakia
  • Site 825
    Zvolen, 960 01, Slovakia
  • Site 353
    Wŏnju, Gangwon-do 26426, South Korea
  • Site 357
    Busan, 48108, South Korea
  • Site 354
    Daegu, 41404, South Korea
  • Site 361
    Daegu, 42601, South Korea
  • Site 355
    Daejeon, 34943, South Korea
  • Site 356
    Seoul, 03312, South Korea
  • Site 362
    Seoul, 06351, South Korea
  • Site 360
    Seoul, 07985, South Korea
  • Site 394
    Changhua, 500, Taiwan
  • Site 392
    Chiayi City, 600, Taiwan
  • Site 395
    Kaohsiung City, 833401, Taiwan
  • Site 396
    Taichung, 404327, Taiwan
  • Site 391
    Taipei, 100225, Taiwan
  • Site 863
    Sakarya, 54290, Turkey (Türkiye)
  • Site 906
    Ivano-Frankivsk, 76008, Ukraine
  • Site 902
    Kyiv, 02002, Ukraine
  • Site 904
    Kyiv, 02091, Ukraine
  • Site 913
    Kyiv, 04050, Ukraine
  • Site 911
    Kyiv, 04106, Ukraine
  • Site 903
    Kyiv, 04210, Ukraine
  • Site 901
    Lutsk, 43005, Ukraine
  • Site 909
    Lviv, 79010, Ukraine
  • Site 914
    Poltava, 36011, Ukraine
  • Site 908
    Vinnytsia, 21009, Ukraine
  • Site 907
    Vinnytsia, 21029, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 32 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 17, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Mar 2, 2029
CompletionEst.
Jan 3, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
48 sites added — first sites in Germany, Austria, Brazil, Mexico, Chile and 1 more
All 6 countries

Germany, Austria, Brazil, Mexico, Chile, Turkey (Türkiye)

Show 48 added (6 Poland, 5 United States, 4 South Korea, 3 Ukraine, 3 Mexico, 2 Georgia, 2 Hungary, 2 Jordan, 2 Serbia, 2 Taiwan, 2 Austria, 2 Brazil, 2 Moldova, 2 Slovakia, 2 Chile, 1 Australia, 1 Germany, 1 Romania, 1 Belgium, 1 Italy, 1 Argentina, 1 Turkey (Türkiye))
  • Site 007 · Kissimmee, United States
  • Site 025 · Providence, United States
  • Site 589 · Marneuli, Georgia
  • Site 750 · Kłodzko, Poland
  • Site 743 · Opole, Poland
  • Site 747 · Wroclaw, Poland
  • Site 355 · Daejeon, South Korea
  • Site 208 · Concord, Australia
  • Site 587 · Tbilisi, Georgia
  • Site 603 · Ulm, Germany
  • Site 652 · Székesfehérvár, Hungary
  • Site 423 · Irbid, Jordan
  • Site 781 · Bucharest, Romania
  • Site 803 · Belgrade, Serbia
  • Site 807 · Belgrade, Serbia
  • Site 354 · Daegu, South Korea
  • Site 394 · Changhua, Taiwan
  • Site 909 · Lviv, Ukraine
  • Site 008 · Southlake, United States
  • Site 463 · Linz, Austria
  • Site 461 · Salzburg, Austria
  • Site 473 · Leuven, Belgium
  • Site 128 · Santo André, Brazil
  • Site 673 · Legnano, Italy
  • Site 421 · Amman, Jordan
  • Site 174 · Saltillo, Mexico
  • Site 175 · Celaya, Mexico
  • Site 173 · Tlajomulco de Zúñiga, Mexico
  • Site 712 · Chisinau, Moldova
  • Site 822 · Košice, Slovakia
  • …and 18 more on the registry record
across 6 updates, Sep 29, 2026 – Nov 9, 2026
Show all 6 updates
  1. Nov 9, 2026
    2 sites added — first site in Turkey (Türkiye)
    Show 2 added (1 Slovakia, 1 Turkey (Türkiye))
    • Site 825 · Zvolen, Slovakia
    • Site 863 · Sakarya, Turkey (Türkiye)
  2. Nov 3, 2026
    7 sites added
    Show 7 added (2 United States, 1 Argentina, 1 Brazil, 1 Hungary, 1 Moldova, 1 Poland)
    • Site 023 · La Jolla, United States
    • Site 028 · Rochester, United States
    • Site 102 · Lujan de Cuyo, Argentina
    • Site 126 · Passo Fundo, Brazil
    • Site 654 · Békéscsaba, Hungary
    • Site 715 · Chisinau, Moldova
    • Site 733 · Szczecin, Poland
    + 1 other change: verification date
  3. Oct 27, 2026
    5 sites added — first site in Chile
    Show 5 added (2 Chile, 2 Poland, 1 South Korea)
    • Site 153 · Osorno, Chile
    • Site 152 · Santiago, Chile
    • Site 748 · Krakow, Poland
    • Site 746 · Lodz, Poland
    • Site 362 · Seoul, South Korea
  4. Oct 19, 2026
    16 sites added — first sites in Austria, Brazil and Mexico
    Show 16 added (3 Mexico, 2 Austria, 2 Ukraine, 1 United States, 1 Belgium, 1 Brazil, 1 Italy, 1 Jordan, 1 Moldova, 1 Slovakia, 1 South Korea, 1 Taiwan)
    • Site 008 · Southlake, United States
    • Site 463 · Linz, Austria
    • Site 461 · Salzburg, Austria
    • Site 473 · Leuven, Belgium
    • Site 128 · Santo André, Brazil
    • Site 673 · Legnano, Italy
    • Site 421 · Amman, Jordan
    • Site 174 · Saltillo, Mexico
    • Site 175 · Celaya, Mexico
    • Site 173 · Tlajomulco de Zúñiga, Mexico
    • Site 712 · Chisinau, Moldova
    • Site 822 · Košice, Slovakia
    • Site 360 · Seoul, South Korea
    • Site 395 · Kaohsiung City, Taiwan
    • Site 908 · Vinnytsia, Ukraine
    • Site 907 · Vinnytsia, Ukraine
  5. Oct 6, 2026
    11 sites added — first site in Germany
    Show 11 added (2 Serbia, 1 Australia, 1 Georgia, 1 Germany, 1 Hungary, 1 Jordan, 1 Romania, 1 South Korea, 1 Taiwan, 1 Ukraine)
    • Site 208 · Concord, Australia
    • Site 587 · Tbilisi, Georgia
    • Site 603 · Ulm, Germany
    • Site 652 · Székesfehérvár, Hungary
    • Site 423 · Irbid, Jordan
    • Site 781 · Bucharest, Romania
    • Site 803 · Belgrade, Serbia
    • Site 807 · Belgrade, Serbia
    • Site 354 · Daegu, South Korea
    • Site 394 · Changhua, Taiwan
    • Site 909 · Lviv, Ukraine
    + 1 other change: verification date
  6. Sep 29, 2026
    7 sites added
    Show 7 added (3 Poland, 2 United States, 1 Georgia, 1 South Korea)
    • Site 007 · Kissimmee, United States
    • Site 025 · Providence, United States
    • Site 589 · Marneuli, Georgia
    • Site 750 · Kłodzko, Poland
    • Site 743 · Opole, Poland
    • Site 747 · Wroclaw, Poland
    • Site 355 · Daejeon, South Korea

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07652294
Lead sponsor
Spyre Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 8, 2026
Primary completion
Mar 2, 2029 (estimated)
Completion
Jan 3, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

SKYLINE Study Director
study director · Spyre Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion